Form 8-K - Current report:
SEC Accession No. 0001193125-25-134908
Filing Date
2025-06-04
Accepted
2025-06-04 16:15:16
Documents
12
Period of Report
2025-06-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d48650d8k.htm   iXBRL 8-K 25856
  Complete submission text file 0001193125-25-134908.txt   136097

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rlay-20250603.xsd EX-101.SCH 2837
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rlay-20250603_lab.xml EX-101.LAB 17234
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rlay-20250603_pre.xml EX-101.PRE 10803
14 EXTRACTED XBRL INSTANCE DOCUMENT d48650d8k_htm.xml XML 3503
Mailing Address 60 HAMPSHIRE STREET CAMBRIDGE MA 02139
Business Address 60 HAMPSHIRE STREET CAMBRIDGE MA 02139 617-370-8837
Relay Therapeutics, Inc. (Filer) CIK: 0001812364 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39385 | Film No.: 251023279
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)